Faruqi & Faruqi, LLP Launches Investigation Against Sarepta Therapeutics Investors

Investigation on Sarepta Therapeutics by Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP, a prominent law firm specializing in securities litigation, has initiated an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT). This investigation is aimed at assessing potential claims on behalf of investors who have suffered financial losses while holding Sarepta's securities between June 22, 2023, and June 24, 2025. The law firm urges impacted investors to reach out and understand their legal rights and options moving forward.

The firm highlights that an important deadline is approaching: August 25, 2025. This date is significant for investors seeking to become lead plaintiffs in the federal securities class action lawsuit filed against Sarepta Therapeutics. Those interested in participating in this legal action or needing further details are encouraged to contact Faruqi & Faruqi's partner, Josh Wilson, directly.

Background of the Investigation

The probe into Sarepta stems from numerous allegations indicating that Sarepta and its management may have violated federal securities laws. Specifically, there are claims that the company made misleading statements regarding the safety and efficacy of its product, ELEVIDYS, which has recently come under scrutiny.

The complaints have surfaced due to alarming reports linking ELEVIDYS to severe safety risks, including deaths from related treatments. For instance, on March 18, 2025, Sarepta announced a safety update stating that a patient had unfortunately died after receiving treatment with ELEVIDYS. Following this news, Sarepta's stock experienced a significant drop, plummeting by nearly 27.44% in a single day.

Further disclosures indicated that regulatory authorities in the European Union had requested an independent committee to review incidents of death associated with the treatment, prompting Sarepta to halt new patient recruitment and clinical trials for the product. Subsequently, on June 15, 2025, a second patient death was reported due to acute liver failure linked to the treatment, resulting in an additional crash of stock value by over 42%.

The final blow occurred on June 24, 2025, when the U.S. Food and Drug Administration (FDA) publicly declared it was investigating the severe adverse outcomes associated with ELEVIDYS, leading to yet another decline in Sarepta’s stock price.

Call to Action for Investors

This ongoing series of troubling news has led Faruqi & Faruqi to encourage anyone who has invested in Sarepta during the specified period and has suffered losses to consider joining the class action lawsuit. Investors are reminded that participation as a lead plaintiff may help in spearheading the litigation process, thus representing the collective interests of all affected shareholders.

If you possess any information regarding Sarepta's practices, including whistleblower details or insights from former employees or shareholders, Faruqi & Faruqi invites you to reach out. Your contributions could be vital in holding the company accountable for its alleged misdeeds and restoring investor confidence.

For more information regarding the ongoing investigation and class action details, investors are encouraged to visit www.faruqilaw.com/SRPT or contact Faruqi & Faruqi directly by phone. Knowledge of legal options is crucial in these circumstances, and affected investors should not hesitate to seek assistance.

Conclusion

As the legal landscape unfolds around Sarepta Therapeutics, the role of investor advocacy through law firms like Faruqi & Faruqi becomes increasingly essential. With looming deadlines and significant claims at stake, investors are urged to stay informed and actively participate in safeguarding their financial interests.